Author

Elżbieta Kania

University of GlasgowORCID 0000-0002-6530-9549Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1 Assay:proteomics· 1

Frequent Co-Authors

Evie RigbyiD· 2 shared Francesca Fasanella MasciiD· 2 shared Karen KeeshaniD· 2 shared Lijun Liu· 2 shared Akshara Narayanan· 1 shared Alastair SmithiD· 1 shared Alexander Winton· 1 shared Alexandra Curran· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Evie RigbyORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

CD180 identifies chemoresistant stem-like blasts and reveals a KMT2A-driven vulnerability in acute myeloid leukaemia

Madonna M. Eltoukhy, Alexander Winton, Francesca Fasanella Masci, Elżbieta Kania, Mary T. Scott, Alastair Smith, Evie Rigby, Alexandra Curran, Aya Gouma, Jennifer E. Cassels, Lijun Liu, Thomas Stevens, Karen M. Dunn, Kevin M. Rattigan, Meaad almowaled, , Karen Keeshan

This paper identifies CD180 as a marker for chemoresistant stem-like blasts in KMT2A-rearranged paediatric AML, showing its absence on normal HSCs and its role as a therapeutic target.

bioRxiv · Apr 27, 2026 · PreprintCancer Biology

Inducing TRIB2 Targeted Protein Degradation to Reverse Chemoresistance in Acute Myeloid Leukemia

Evie Rigby, Francesca Fasanella Masci, Akshara Narayanan, Elżbieta Kania, John A. Harris, Jamie J.L. Williams, Binghua Zhang, Lijun Liu, Laura Richmond, Fengtao Zhou, Ke Ding, Ruaidhrı́ J. Carmody, Patrick A. Eyers, Karen Keeshan

This study identifies TRIB2 as a therapeutic target in AML by demonstrating that its degradation via PROTACs and small molecules can reverse chemoresistance and enhance chemotherapy efficacy.

Biochemical Journal · Mar 13, 2026Peer-reviewedCancer Biology